HKSE - Delayed Quote HKD

Simcere Pharmaceutical Group Limited (2096.HK)

8.530

-0.270

(-3.07%)

At close: April 25 at 4:08:21 PM GMT+8

Fermion and Simcere Enter into an Exclusive License and Collaboration Agreement for China's First SSTR4 Agonist Targeting Pain

Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4.

PR Newswire 3 months ago

SMHGF
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and the U.S.

PR Newswire 3 months ago

SMHGF
AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and the U.S.

PR Newswire 3 months ago

SMHGF

ABBV
China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke

On November 2, 2024, Simcere Pharmaceutical announced that Sanbexin® sublingual tablets (generic name: edaravone and dexborneol sublingual tablets), an innovative drug for stroke, has been approved for marketing by the National Medical Products Administration. This product is indicated for the improvement of neurological symptoms, daily activities, and functional impairment due to acute ischemic stroke.

PR Newswire 4 months ago

SMHGF
World Stroke Congress | TASTE-2 significantly reduces stroke disability

Oct 24th 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that a new clinical study with major clinical findings regarding Sanbexin (edaravone and dexborneol concentrated solution for injection) has been published at the 16th World Stroke Conference (WSC). According to the latest data, the administration of edaravone dexborneol (Sanbexin®) in patients with acute ischemic stroke (AIS) before receiving endovascular thrombectomy significantly improved neuro-function recovery and reduced

PR Newswire 5 months ago

SMHGF
TASTE-2 World Stroke Congress | Sanbexin ® combined with thrombectomy significantly reduces stroke disability

On October 24, 2024, TASTE-2, a Chinese innovative stroke drug study led by Professor Wang Yongjun from Beijing Tiantan Hospital, was published in an oral report at the 16th World Stroke Conference (WSC): brain cell protection combined with edaravone dexborneol (Sanbexin ®) in patients with acute ischemic stroke before endovascular thrombectomy significantly improved the proportion of patients who recovered neurological independence at 90 days and reduced the proportion of patients with disabili

PR Newswire 5 months ago

SMHGF
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Ischemic Stroke (AIS). Sanbexin sublingual tablets is the first innovative drug in the world to be designated with the Breakthrough Therapy by the FDA for the treatment of stroke.

PR Newswire 7 months ago

SMHGF
Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor

On September 02, 2024, Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), announced a collaboration agreement with Shenzhen TargetRx Inc. The partnership focuses on the ALK/ROS1 dual receptor tyrosine kinase inhibitor TGRX-326, a clinical-stage anti-tumor candidate.

PR Newswire 7 months ago

SMHGF
Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA

On June 25, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that Enlituo® (generic name: cetuximab beta injection), a new generation anti-epidermal growth factor receptor (EGFR) antibody drug developed in collaboration with Mabpharm Limited (2181.HK), has recently received approval from the China National Medical Administration (NMPA) for marketing. Enlituo® is indicated for use in combination with the FOLFIRI regimen as

PR Newswire 9 months ago

SMHGF

Performance Overview

Return	2096.HK	HANG SENG INDEX (^HSI)
YTD	+21.51%	+9.58%
1-Year	+67.74%	+27.17%
3-Year	+15.25%	+10.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Simcere Pharmaceutical Group Limited (2096.HK)

Fermion and Simcere Enter into an Exclusive License and Collaboration Agreement for China's First SSTR4 Agonist Targeting Pain

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke

World Stroke Congress | TASTE-2 significantly reduces stroke disability

TASTE-2 World Stroke Congress | Sanbexin ® combined with thrombectomy significantly reduces stroke disability

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor

Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA

Performance Overview